Please use this identifier to cite or link to this item: https://doi.org/10.3791/62638
DC FieldValue
dc.titleRetinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
dc.contributor.authorSeah, Ivan
dc.contributor.authorLIU ZENGPING
dc.contributor.authorWONG SOO LIN
dc.contributor.authorWong, Wendy
dc.contributor.authorHolder, Graham E
dc.contributor.authorVELUCHAMY AMUTHA BARATHI
dc.contributor.authorLINGAM GOPAL
dc.contributor.authorSU XINYI
dc.contributor.authorStanzel, Boris
dc.date.accessioned2021-11-19T06:36:50Z
dc.date.available2021-11-19T06:36:50Z
dc.date.issued2021-06-01
dc.identifier.citationSeah, Ivan, LIU ZENGPING, WONG SOO LIN, Wong, Wendy, Holder, Graham E, VELUCHAMY AMUTHA BARATHI, LINGAM GOPAL, SU XINYI, Stanzel, Boris (2021-06-01). Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases. JOVE-JOURNAL OF VISUALIZED EXPERIMENTS 2021 (172). ScholarBank@NUS Repository. https://doi.org/10.3791/62638
dc.identifier.issn1940-087X
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/206772
dc.description.abstractRetinal pigment epithelial (RPE) transplantation holds great promise for the treatment of inherited and acquired retinal degenerative diseases. These conditions include retinitis pigmentosa (RP) and advanced forms of age-related macular degeneration (AMD), such as geographic atrophy (GA). Together, these disorders represent a significant proportion of currently untreatable blindness globally. These unmet medical needs have generated heightened academic interest in developing methods of RPE replacement. Among the animal models commonly utilized for preclinical testing of therapeutics, the non-human primate (NHP) is the only animal model that has a macula. As it shares this anatomical similarity with the human eye, the NHP eye is an important and appropriate preclinical animal model for the development of advanced therapy medicinal products (ATMPs) such as RPE cell therapy. This manuscript describes a method for the submacular transplantation of an RPE monolayer, cultured on a polyethylene terephthalate (PET) cell carrier, underneath the macula onto a surgically created RPE wound in immunosuppressed NHPs. The fovea-the central avascular portion of the macula-is the site of the greatest mechanical weakness during the transplantation. Foveal trauma will occur if the initial subretinal fluid injection generates an excessive force on the retina. Hence, slow injection under perfluorocarbon liquid (PFCL) vitreous tamponade is recommended with a dual-bore subretinal injection cannula at low intraocular pressure (IOP) settings to create a retinal bleb. Pretreatment with an intravitreal plasminogen injection to release parafoveal RPEphotoreceptor adhesions is also advised. These combined strategies can reduce the likelihood of foveal tears when compared to conventional techniques. The NHP is a key animal model in the preclinical phase of RPE cell therapy development. This protocol addresses the technical challenges associated with the delivery of RPE cellular therapy in the NHP eye.
dc.language.isoen
dc.publisherJOURNAL OF VISUALIZED EXPERIMENTS
dc.sourceElements
dc.subjectScience & Technology
dc.subjectMultidisciplinary Sciences
dc.subjectScience & Technology - Other Topics
dc.subjectSTEM-CELLS
dc.subjectOCRIPLASMIN
dc.subjectEFFICACY
dc.subjectDELIVERY
dc.subjectSAFETY
dc.typeArticle
dc.date.updated2021-11-18T15:35:55Z
dc.contributor.departmentDEPT OF OPHTHALMOLOGY
dc.description.doi10.3791/62638
dc.description.sourcetitleJOVE-JOURNAL OF VISUALIZED EXPERIMENTS
dc.description.volume2021
dc.description.issue172
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
P24 Ivan NHP protocol JoVE 2021.pdf1.28 MBAdobe PDF

OPEN

PublishedView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.